Literature DB >> 30103302

Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.

Jiali Wu, Zheyi Xiang, Le Bai, Lagu He, Li Tan, Min Hu, Yaping Ren.   

Abstract

BACKGROUND: It is reported that prothrombin induced by vitamin K absence-II (PIVKA-II) has a better performance of diagnosis for HCC, and has also been known to be an independent risk factor for vascular invasion. Few studies study the relationship between PIVKA-II and HBV DNA.
OBJECTIVE: To determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its relationship with vascular invasion and HBV DNA.
METHODS: In a Chinese cohort, we conducted a case-control study to compare the performances of a-fetoprotein (AFP) and PIVKA-II serum levels for diagnosis of HCC and early HCC. Fifty one healthy controls, 37 chronic hepatitis patients, 43 cirrhotic patients and 143 HCC cases of which 48 (33.57%) had early stage HCC (n= 19 very early, n= 29 early) were enrolled. We explored the correlation between PIVKA-II serum level and several pathological features such as vascular invasion. The serum levels of and AFP were measured by chemiluminescence assay (CLIA) and electrochemiluminescence assay (ECLA).
RESULTS: The serum levels of both PIVKA-II and AFP in HCC group were higher than that in chronic hepatitis, cirrhosis and healthy control groups. The sensitivity, specificity, positive predictive value, negative predictive value and kappa of PIVKA-II were higher than AFP in the diagnosis of HCC. Serum PIVKA-II level was correlated with tumor size, tumor cell differentiation and BCLC staging (P< 0.05). For the diagnosis of early HCC, the combination of PIVKA-II (AUC 0.812; 95% CI, 0.702-0.894) and AFP (0.797; 95% CI, 0.686-0.883) slightly improve the diagnostic performance for early HCC(AUC 0.849; 95% CI, 0.745-0.923). PIVKA-II > 166 mAU/ml is an independent risk factor for vascular invasion. The serum HBV DNA level in cirrhosis and HCC patients was significantly higher than in chronic hepatitis patients. We detected a negative association between serum PIVKA-II and serum HBV DNA levels.
CONCLUSIONS: PIVKA-II was more efficient than AFP for the diagnosis of early HCC and has no correlation with serum HBV DNA levels.

Entities:  

Keywords:  HBV DNA load; Hepatocellular carcinoma; alpha fetoprotein; prothrombin induced by vitamin K absence-II; vascular invasion

Mesh:

Substances:

Year:  2018        PMID: 30103302     DOI: 10.3233/CBM-181402

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  9 in total

1.  Performance evaluation of the Elecsys PIVKA-II and Elecsys AFP assays for hepatocellular carcinoma diagnosis.

Authors:  Henry L Y Chan; Arndt Vogel; Thomas Berg; Enrico N De Toni; Masatoshi Kudo; Jörg Trojan; Anja Eiblmaier; Hanns-Georg Klein; Johannes Kolja Hegel; Ashish Sharma; Kairat Madin; Vinzent Rolny; Marcus-Rene Lisy; Teerha Piratvisuth
Journal:  JGH Open       Date:  2022-05-07

2.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

3.  Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C.

Authors:  S I Malov; I V Malov; A G Kuvshinov; P N Marche; T Decaens; Z Macek-Jilkova; N D Yushchuk
Journal:  Sovrem Tekhnologii Med       Date:  2021-02-28

4.  Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients.

Authors:  Brian I Carr; Volkan Ince; Harika Gozukara Bag; Veysel Ersan; Sertac Usta; Sezai Yilmaz
Journal:  Clin Pract (Lond)       Date:  2020

5.  Diagnostic value of gamma-glutamyltransferase/aspartate aminotransferase ratio, protein induced by vitamin K absence or antagonist II, and alpha-fetoprotein in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Qiang Wang; Qi Chen; Xia Zhang; Xiao-Lan Lu; Qin Du; Tao Zhu; Guo-Yuan Zhang; Dong-Sheng Wang; Qu-Ming Fan
Journal:  World J Gastroenterol       Date:  2019-09-28       Impact factor: 5.742

6.  Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients.

Authors:  Youran Chen; Yanyan Yang; Shanshan Li; Minghao Lin; Xueting Xie; Huifang Shi; Yuchun Jiang; Sijie Zheng; Hui Shao; Naibin Yang; Mingqin Lu
Journal:  Front Public Health       Date:  2022-01-25

Review 7.  Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.

Authors:  Yang Yang; Guangbing Li; Ziwen Lu; Yong Liu; Junjie Kong; Jun Liu
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

8.  The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.

Authors:  Fei Xu; Lulu Zhang; Wenting He; Di Song; Xiaomeng Ji; Jianyong Shao
Journal:  Dis Markers       Date:  2021-02-08       Impact factor: 3.434

9.  Clinical Utility of Protein Induced by Vitamin K Absence-II in Patients with Hepatocellular Carcinoma.

Authors:  Abu Bakar Hafeez H Bhatti; Kiran Naz; Ghazanfar Abbas; Nusrat Y Khan; Haseeb H Zia; Imran N Ahmed
Journal:  Asian Pac J Cancer Prev       Date:  2021-06-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.